• If you are wondering whether Vertex Pharmaceuticals at around US$492 per share is still a good deal or already pricing in a lot of optimism, you are asking the right question for any valuation focused investor.
• The stock has returned 3.0% over the last week, 4.6% over the last month, 8.9% year to date, while the 1 year return sits at a slight 0.6% decline and the 3 and 5 year returns are 67.3% and 126.8% respectively. This naturally raises questions about how much of the story is already in the price.
• Recent coverage around Vertex has kept attention on its position in the pharmaceuticals and biotech space and the long term return profile that has built up over several years. This context helps explain why investors are now closely weighing shorter term moves against a much stronger multi year track record.
• On our valuation checks, Vertex scores 3 out of 6, which you can see in detail in our valuation score. Next we will look at what different valuation approaches say about that number before finishing with a way to interpret valuation that goes beyond a single score.

Approach 1: Vertex Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and then discounts them back to what they might be worth today, based on the time value of money and risk. It is essentially asking what a stream of future cash in your hand is worth in US$ right now.

For Vertex Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow sits at about US$3.18b. Analysts have provided free cash flow estimates out to 2030, with a projection of US$7.81b in that year, and Simply Wall St extrapolates further years to complete the 10 year path using these cash flow projections.

After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about US$790 per share. Compared with the recent share price around US$492, the DCF output suggests the stock is about 37.7% undervalued on this set of assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 37.7%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Vertex Pharmaceuticals Price vs Earnings

For profitable companies like Vertex Pharmaceuticals, the P/E ratio is a useful way to see how much you are paying for each dollar of current earnings. Higher expected growth and lower perceived risk usually justify a higher P/E, while lower growth or higher risk tend to pull a fair multiple down.

Vertex currently trades on a P/E of 31.64x. That sits above the Biotechs industry average of 21.46x, but below the peer group average of 40.38x, so the raw comparisons send a mixed signal about how demanding the market price is.

Simply Wall St also calculates a Fair Ratio of 29.84x for Vertex. This is the P/E level it estimates would be reasonable given factors like earnings growth, industry, profit margins, market cap and key risks. This Fair Ratio offers a more tailored yardstick than a simple peer or industry comparison because it adjusts for the company’s own profile rather than treating all biotechs as alike.

Set against the actual P/E of 31.64x, the Fair Ratio of 29.84x suggests the shares are trading a little above that tailored estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Vertex Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, a simple way for you to write the story you believe about Vertex Pharmaceuticals and then tie that story to specific assumptions for future revenue, earnings, margins and a Fair Value you can compare to today’s price.

On Simply Wall St, Narratives live in the Community page and let you connect three pieces in one place: the business story, the financial forecast and the Fair Value that falls out of your assumptions. This lets you quickly see whether your view suggests the shares look cheap or expensive right now.

Because Narratives update automatically when new information like earnings, guidance or news is added, you are not stuck with a static DCF or P/E snapshot. You can see how your Fair Value moves as the Vertex Pharmaceuticals story evolves.

For example, one Vertex Pharmaceuticals Narrative on Simply Wall St currently anchors on a Fair Value of about US$403.80 while another uses about US$604.00. This shows how two investors looking at the same company and the same share price can reasonably land on very different decisions about whether the current price looks attractive or stretched based on their own story and numbers.

For Vertex Pharmaceuticals however we'll make it really easy for you with previews of two leading Vertex Pharmaceuticals Narratives:

Fair Value: US$504.04 per share

Current price vs this Fair Value: around 2.3% below that Narrative estimate

Revenue growth used in this Narrative: 6.98%

• Positions Vertex as evolving from a pure cystic fibrosis focus into a broader multi disease company, with products in pain, hematology and kidney disease alongside a large cash position to fund more programs.
• Highlights the role of new therapies like Alyftrek, Casgevy and Suzetrigine in supporting revenue and creating a second phase of the story as the original CF franchise matures.
• Arrives at a Fair Value of about US$504 using a multi stage DCF approach, tying that to a quality growth at a reasonable price profile with a focus on margins and capital returns.

Fair Value: US$403.80 per share

Current price vs this Fair Value: around 22.0% above that Narrative estimate

Revenue growth used in this Narrative: 3.16%

• Raises concerns that heavy reliance on high priced therapies and complex gene editing treatments could be pressured by tighter regulation, access constraints and rising R&D costs.
• Emphasizes concentration in rare genetic diseases and potential competition in CF and other core areas as key risks for earnings stability and long term market share.
• Anchors on a Fair Value near US$404 that sits below the recent share price, using more cautious assumptions on revenue growth, margins and valuation multiples compared with more optimistic analyst views.

Together these Narratives frame a clear range of views around Vertex, from those who see the current price as roughly in line with quality long term growth to those who think expectations have run ahead of what the business profile and risk set justify right now.

Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.